| pubmed-article:9322871 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9322871 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9322871 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
| pubmed-article:9322871 | lifeskim:mentions | umls-concept:C0882849 | lld:lifeskim |
| pubmed-article:9322871 | lifeskim:mentions | umls-concept:C0442335 | lld:lifeskim |
| pubmed-article:9322871 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:9322871 | pubmed:dateCreated | 1997-11-6 | lld:pubmed |
| pubmed-article:9322871 | pubmed:abstractText | High transduction frequency of hematopoietic stem/progenitor cells is essential to derive clinical benefits for treating certain inherited and acquired diseases. We demonstrate here stable gene transfer into human bone marrow-derived CD34+ progenitors using cationic lipids to facilitate GaLV and amphotroic pseudotyped retroviral-mediated transductions. Furthermore, the transgene was detected only in the progeny of flow cytometer sorted CD34+ population transduced by the LAPSN (PG13) viral vector in the presence of cationic lipids but not when transduction was facilitated with conventional polycations Polybrene or protamine sulfate. Thus, a combination of GaLV pseudotyped vectors and cationic lipids results in increased transduction frequencies of the CD34+ cells without a requirement of extended in vitro culture, or co-cultivation with producer cell lines. These improvements may result in the production of therapeutically significant quantities of genetically modified hematopoietic cells. | lld:pubmed |
| pubmed-article:9322871 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9322871 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9322871 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9322871 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9322871 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9322871 | pubmed:issn | 1043-0342 | lld:pubmed |
| pubmed-article:9322871 | pubmed:author | pubmed-author:KingJ WJWJr | lld:pubmed |
| pubmed-article:9322871 | pubmed:author | pubmed-author:HareTT | lld:pubmed |
| pubmed-article:9322871 | pubmed:author | pubmed-author:AnklesariaPP | lld:pubmed |
| pubmed-article:9322871 | pubmed:author | pubmed-author:LynchC MCM | lld:pubmed |
| pubmed-article:9322871 | pubmed:author | pubmed-author:DybingJJ | lld:pubmed |
| pubmed-article:9322871 | pubmed:author | pubmed-author:JurusLL | lld:pubmed |
| pubmed-article:9322871 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9322871 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:9322871 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:9322871 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9322871 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9322871 | pubmed:pagination | 1685-94 | lld:pubmed |
| pubmed-article:9322871 | pubmed:dateRevised | 2006-4-21 | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:meshHeading | pubmed-meshheading:9322871-... | lld:pubmed |
| pubmed-article:9322871 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9322871 | pubmed:articleTitle | GaLV pseudotyped vectors and cationic lipids transduce human CD34+ cells. | lld:pubmed |
| pubmed-article:9322871 | pubmed:affiliation | Targeted Genetics Corporation, Seattle, WA 98101, USA. | lld:pubmed |
| pubmed-article:9322871 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9322871 | lld:pubmed |
